On December 12, 2022 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that Roche issued a press release on data presentation regarding therapeutic antibodies created by Chugai, Hemlibra and crovalimab, at the American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting (Press release, Chugai, DEC 12, 2022, View Source [SID1234625097]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Please refer to the link below for details:

Interim data from phase III study presented at ASH (Free ASH Whitepaper) 2022 show Hemlibra achieved meaningful bleed control in infants from birth
View Sourceb" target="_blank" title="View Sourceb" rel="nofollow">View Source
Roche’s subcutaneous crovalimab given every four weeks achieves disease control in people with PNH, a life-threatening blood condition
View Source